Compare Stocks: AMIX, BRNS, SYRE, and MDXH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMIX Autonomix Medical	$3.83 -4.7%	$5.58	$2.44 ▼ $32.55	$3.90M	-1	106,223 shs	74,152 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.66	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
MDXH MDxHealth	$0.55 -3.0%	$0.60	$0.40 ▼ $5.33	$27.98M	1.57	206,844 shs	94,656 shs
SYRE Spyre Therapeutics	$85.79 +0.1%	$96.66	$15.49 ▼ $110.18	$7.54B	2.99	1.22 million shs	1.05 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMIX Autonomix Medical	0.00%	-4.51%	-24.44%	-31.16%	-81.77%
BRNS Barinthus Biotherapeutics	0.00%	+0.01%	-0.83%	+12.03%	-39.34%
MDXH MDxHealth	0.00%	-10.29%	-21.58%	+41.30%	-87.79%
SYRE Spyre Therapeutics	0.00%	-5.05%	-5.17%	-4.96%	+427.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMIX Autonomix Medical	$3.83 -4.7%	$5.58	$2.44 ▼ $32.55	$3.90M	-1	106,223 shs	74,152 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.66	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
MDXH MDxHealth	$0.55 -3.0%	$0.60	$0.40 ▼ $5.33	$27.98M	1.57	206,844 shs	94,656 shs
SYRE Spyre Therapeutics	$85.79 +0.1%	$96.66	$15.49 ▼ $110.18	$7.54B	2.99	1.22 million shs	1.05 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMIX Autonomix Medical	0.00%	-4.51%	-24.44%	-31.16%	-81.77%
BRNS Barinthus Biotherapeutics	0.00%	+0.01%	-0.83%	+12.03%	-39.34%
MDXH MDxHealth	0.00%	-10.29%	-21.58%	+41.30%	-87.79%
SYRE Spyre Therapeutics	0.00%	-5.05%	-5.17%	-4.96%	+427.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMIX Autonomix Medical	2.00	Hold	$42.00	996.61% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.47% Upside
MDXH MDxHealth	2.40	Hold	$2.17	295.38% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	27.86% Upside

Current Analyst Ratings Breakdown

Latest AMIX, BRNS, SYRE, and MDXH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	MDXH MDxHealth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
9/1/2026	SYRE Spyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	$10.85 per share	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
MDXH MDxHealth	$107.88M	0.25	N/A	N/A	($0.24) per share	-2.28
SYRE Spyre Therapeutics	$890K	8,476.82	N/A	N/A	$7.21 per share	11.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMIX Autonomix Medical	-$16.72M	-$41.57	N/A	N/A	N/A	N/A	-267.73%	-216.75%	11/11/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest AMIX, BRNS, SYRE, and MDXH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/12/2026	Q1 2027	AMIX Autonomix Medical	-$6.40	-$5.02	+$1.38	-$5.02	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMIX Autonomix Medical	N/A	4.85	4.85
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
MDXH MDxHealth	N/A	1.15	0.98
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMIX Autonomix Medical	10.78%
BRNS Barinthus Biotherapeutics	25.20%
MDXH MDxHealth	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
AMIX Autonomix Medical	5.50%
BRNS Barinthus Biotherapeutics	8.50%
MDXH MDxHealth	1.70%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMIX Autonomix Medical	11	970,000	918,000	N/A
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
MDXH MDxHealth	364	49.50 million	48.66 million	Not Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable

AMIX, BRNS, SYRE, and MDXH Headlines

Recent News About These Companies

Analyzing Surrozen (NASDAQ:SRZN) & Spyre Therapeutics (NASDAQ:SYRE)

September 24, 2026 | americanbankingnews.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by Brokerages

September 20, 2026 | americanbankingnews.com

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

September 17, 2026 | finance.yahoo.com

Financial Contrast: Spyre Therapeutics (NASDAQ:SYRE) vs. Genmab A/S (NASDAQ:GMAB)

September 17, 2026 | americanbankingnews.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Moderate Buy" from Analysts

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Increases Stake in Spyre Therapeutics, Inc. $SYRE

September 15, 2026 | marketbeat.com

Engineers Gate Manager LP Takes $3.42 Million Position in Spyre Therapeutics, Inc. $SYRE

September 14, 2026 | marketbeat.com

11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

September 14, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

September 10, 2026 | insidermonkey.com

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results

September 9, 2026 | blockonomi.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

September 9, 2026 | zacks.com

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

September 9, 2026 | marketbeat.com

Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

September 9, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...

September 8, 2026 | markets.businessinsider.com

Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

September 8, 2026 | rttnews.com

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

September 8, 2026 | finance.yahoo.com

Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research

September 8, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What Happened

September 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMIX, BRNS, SYRE, and MDXH Company Descriptions

Autonomix Medical NASDAQ:AMIX

$3.83 -0.19 (-4.73%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 +0.05 (+1.31%)

As of 07:30 PM Eastern

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 09/25/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

MDxHealth NASDAQ:MDXH

$0.55 -0.02 (-3.04%)

Closing price 04:00 PM Eastern

Extended Trading

$0.55 +0.01 (+0.91%)

As of 06:30 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Spyre Therapeutics NASDAQ:SYRE

$85.79 +0.10 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$85.82 +0.03 (+0.03%)

As of 07:34 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMIX, BRNS, SYRE, and MDXH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMIX, BRNS, SYRE, and MDXH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMIX, BRNS, SYRE, and MDXH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMIX, BRNS, SYRE, and MDXH Company Descriptions

Autonomix Medical NASDAQ:AMIX

Barinthus Biotherapeutics NASDAQ:BRNS

MDxHealth NASDAQ:MDXH

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMIX, BRNS, SYRE, and MDXH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMIX, BRNS, SYRE, and MDXH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMIX, BRNS, SYRE, and MDXH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMIX, BRNS, SYRE, and MDXH Company Descriptions

Autonomix Medical NASDAQ:AMIX

Barinthus Biotherapeutics NASDAQ:BRNS

MDxHealth NASDAQ:MDXH

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools